FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Emanuela Salvatorelli

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Co-author Network

Publications

TOP 3
Emanuela Salvatorelli; Jack W Singer; Odalys Gonzalez Paz; Massimo Chello; Elvio Covino; Pierantonio Menna; Giorgio Minotti
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
Emanuela Salvatorelli; Consiglia Carella; Antonella Colasante; Michele De Tursi; Stefano Iacobelli; Renato Massari; Pierantonio Menna; Giorgio Minotti
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.
Emanuela Salvatorelli; Victoria Sung; Sekhar Surapaneni; Sharon L Aukerman; Massimo Chello; Elvio Covino; Odalys Gonzalez Paz; Pierantonio Menna; Giorgio Minotti
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Emanuela Salvatorelli (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Emanuela Salvatorelli; Jack W Singer; Odalys Gonzalez Paz; Massimo Chello; Elvio Covino; Pierantonio Menna; Giorgio Minotti
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
The Journal of pharmacology and experimental therapeutics 2013;344(2):467-78.
2012: Emanuela Salvatorelli; Consiglia Carella; Antonella Colasante; Michele De Tursi; Stefano Iacobelli; Renato Massari; Pierantonio Menna; Giorgio Minotti
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(12):2365-73.
2012: Emanuela Salvatorelli; Victoria Sung; Sekhar Surapaneni; Sharon L Aukerman; Massimo Chello; Elvio Covino; Odalys Gonzalez Paz; Pierantonio Menna; Giorgio Minotti
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
The Journal of pharmacology and experimental therapeutics 2012;341(2):474-83.
2012: Emanuela Salvatorelli; Victoria Sung; Sekhar Surapaneni; Sharon L Aukerman; Massimo Chello; Elvio Covino; Pierantonio Menna; Giorgio Minotti
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.
The Journal of pharmacology and experimental therapeutics 2012;341(2):464-73.
2012: Pierantonio Menna; Massimo Chello; Elvio Covino; Emanuela Salvatorelli; Odalys Gonzalez Paz; Giorgio Minotti
Anthracycline cardiotoxicity.
Expert opinion on drug safety 2012;11 Suppl 1():S21-36.
2011: Fabio Cacciapaglia; Pierantonio Menna; Giorgio Minotti; Luca Navarini; Emanuela Salvatorelli; Antonella Afeltra
Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.
Autoimmunity reviews 2011;10(10):631-5.
2010: Giorgio Minotti; Emanuela Salvatorelli; Pierantonio Menna
Pharmacological foundations of cardio-oncology.
The Journal of pharmacology and experimental therapeutics 2010;334(1):2-8.
2008: Pierantonio Menna; Emanuela Salvatorelli; Giorgio Minotti
Cardiotoxicity of antitumor drugs.
Chemical research in toxicology 2008;21(5):978-89.
2008: Pierantonio Menna; Luca Gianni; Emanuela Salvatorelli; Giorgio Minotti
Anthracycline cardiotoxicity.
Topics in current chemistry 2008;283():21-44.
2007: Pierantonio Menna; Emanuela Salvatorelli; Giorgio Minotti
Doxorubicin degradation in cardiomyocytes.
The Journal of pharmacology and experimental therapeutics 2007;322(1):408-19.
2007: Emanuela Salvatorelli; Pierantonio Menna; Luca Gianni; Giorgio Minotti
Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.
The Journal of pharmacology and experimental therapeutics 2007;320(2):790-800.
2007: Luca Gianni; Emanuela Salvatorelli; Giorgio Minotti
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Cardiovascular toxicology 2007;7(2):67-71.
2007: Pierantonio Menna; Giorgio Minotti; Emanuela Salvatorelli
In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
Cell biology and toxicology 2007;23(1):49-62.
2006: Emanuela Salvatorelli; Pierantonio Menna; Sabrina Cascegna; Giovanni Liberi; Antonio M Calafiore; Luca Gianni; Giorgio Minotti
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies.
The Journal of pharmacology and experimental therapeutics 2006;318(1):424-33.
2006: Emanuela Salvatorelli; Simone Guarnieri; Pierantonio Menna; Giovanni Liberi; Antonio M Calafiore; Maria A Mariggiò; Alvaro Mordente; Luca Gianni; Giorgio Minotti
Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.
The Journal of biological chemistry 2006;281(16):10990-1001.
2004: Giorgio Minotti; Pierantonio Menna; Emanuela Salvatorelli; Gaetano Cairo; Luca Gianni
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.
Pharmacological reviews 2004;56(2):185-229.
2004: Cristiana Sessa; Antonella Perotti; Emanuela Salvatorelli; Giorgio Minotti; Lucia Viganò; Anna Lladò; Giuseppe Capri; Alberta Locatelli; S Colombini; Fedro Alessandro Peccatori; Maurizio Voi; Silvia Marsoni; Luca Gianni
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.
European journal of cancer (Oxford, England : 1990) 2004;40(4):563-70.
2004: Antonella Cartoni; Pierantonio Menna; Emanuela Salvatorelli; Daniela Braghiroli; Rossella Giampietro; Fabio Animati; Andrea Urbani; Piero Del Boccio; Giorgio Minotti
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin.
The Journal of biological chemistry 2004;279(7):5088-99.
2004: Giorgio Minotti; Stefania Recalcati; Pierantonio Menna; Emanuela Salvatorelli; Gianfranca Corna; Gaetano Cairo
Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms.
Methods in enzymology 2004;378():340-61.
2003: Giuseppe Sacco; Rossella Giampietro; Emanuela Salvatorelli; Pierantonio Menna; Nicoletta Bertani; Gallia Graiani; Fabio Animati; Cristina Goso; Carlo Alberto Maggi; Stefano Manzini; Giorgio Minotti
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.
British journal of pharmacology 2003;139(3):641-51.
2002: Pierantonio Menna; Emanuela Salvatorelli; Rossella Giampietro; Giovanni Liberi; Giovanni Teodori; Antonio M Calafiore; Giorgio Minotti
Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines.
Chemical research in toxicology 2002;15(9):1179-89.
2001: Giorgio Minotti; Raffaella Ronchi; Emanuela Salvatorelli; Pierantonio Menna; Gaetano Cairo
Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Cancer research 2001;61(23):8422-8.
2001: Giorgio Minotti; Massimo Parlani; Emanuela Salvatorelli; Pierantonio Menna; A Cipollone; Fabio Animati; Carlo Alberto Maggi; Stefano Manzini
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.
British journal of pharmacology 2001;134(6):1271-8.